Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13MXzLbY5ie2ViQYPzZZk>NHXIcoIzPCCqMX;Jcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>?MVKyOFY1OTFyMx?=
COLO205NE\nTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX:3NkBpNIfLeJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>?M4nmbFI1PjRzMUCz
U937MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{GxfVczKGh?NInYZY5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txOMoDENlQ3PDFzMEO=
MOLM13MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTHXYY4OiCqMlXRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=>M2rJXFI1PjRzMUCz
MOLM13NGfPSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIf6R2Y4OiCqNE\WbmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryPM17qcVI1PjRzMUCz
MDA-MB-435MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XJR|I1KGh?MXrJR|UxRTBwMU[g{txONIHpPJMyPThyMUizNS=>
K562NYfWbYZNS3m2b4TvfIlkKEG|c3H5NILpWHU6PiCqNV:3WGZSTE2VTx?=MWXJR|UxRTJizszNNV3jVYtwOjR2MUe1OlY>
DU145MX;DfZRwfG:6aXOgRZN{[Xl?NInUUHM6PiCqNYjUN2tiTE2VTx?=M1OzdGlEPTB;Nz61JO69VQ>?NIjkRZgzPDRzN{W2Oi=>
MDA-MB-231NYr5TFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXKxJO69VQ>?NIjJdoQzPCCqMXjEUXNQMl\LR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlNULXNJFjOjR2MUe1OlY>
MCF7M1fYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mly2NUDPxE1?MnyyNlQhcA>?M3S2emROW09?NHfidppE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>M1vZ[lI1PDF5NU[2
MCF7NIDaflBMcW6jc3WgRZN{[Xl?MXu1JO69VQ>?M1ryRlI1KGh?NESwZ2RFVVORM2LqRmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=MmjFNlQ1OTd3Nk[=
MDA-MB-231M4G5dGtqdmG|ZTDBd5NigQ>?Mn7DOUDPxE1?M2nU[|I1KGh?NH;ONG9FVVORMlmzTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=NYjqUnZpOjR2MUe1OlY>
MDA-MB-231NHTDSG5HfW6ldHnvckBCe3OjeR?=NYTuVo1GOS1zMDFOwG0>MUWyOEBpNF3IXlBFVVORNXr0S3gx\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflMVuyOFQyPzV4Nh?=
MCF7MmK1SpVv[3Srb36gRZN{[Xl?MnPtNU0yOCEQvF2=MYeyOEBpMWnEUXNQMmLM[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenMmjQNlQ1OTd3Nk[=
MDA-MB-231MUXGeY5kfGmxbjDBd5NigQ>?M2r0clAvPS1zIN88US=>NI\ibnk1QCCqM{LxUGROW09?NE\NVINp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?MlTxNlQ1OTd3Nk[=
MCF7MmjDSpVv[3Srb36gRZN{[Xl?M2ezR|AvPS1zIN88US=>MXS0PEBpM1LTOmROW09?M37GNYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNmMYiyOFQyPzV4Nh?=
697M3rleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TDOmlEPTB;MUS4MlM5KG6PNXuzcG1xW0GQR1XS
P12-ICHIKAWAMnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PFbWlEPTB;OU[uNFQhdk1?MVTTRW5ITVJ?
NB69MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{KyXmlEPTB;MU[xMlghdk1?M{nEenNCVkeHUh?=
EoL-1Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTF6Nz6yOkBvVQ>?M3jyd3NCVkeHUh?=
BHT-101NXXUbJNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfEUFFKSzVyPUG5PE4zPSCwTR?=NIDFeIhUSU6JRWK=
SK-NEP-1Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDVdolLUUN3ME2yNlAvODJibl2=NILDPWVUSU6JRWK=
MHH-NB-11NGGxd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7FbGpQUUN3ME2yNlAvOTlibl2=MUnTRW5ITVJ?
AsPC-1MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTQUXFKSzVyPUK1Nk42OyCwTR?=NHXEeWNUSU6JRWK=
ES1M36wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLKTWM2OD1{NU[uNlUhdk1?MkHQV2FPT0WU
LAMA-84MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFj6coxKSzVyPUK1PE4yQSCwTR?=Mo\NV2FPT0WU
MOLT-16NFy3XmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnBOYFKSzVyPUK1PE41QSCwTR?=Mlm4V2FPT0WU
ES7NV70booyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTMTWM2OD1{N{OuNFkhdk1?MXzTRW5ITVJ?
KY821M4myOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTNzND6xJI5ONITYW3hUSU6JRWK=
RT-112M1nOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXiTWM2OD1|MkGuNFUhdk1?M4nySHNCVkeHUh?=
HL-60M4r0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYW0T|hqUUN3ME2zOFAvPjZibl2=M4i2bXNCVkeHUh?=
MOLT-4MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTGd3lJUUN3ME2zOFUvOTNibl2=MUHTRW5ITVJ?
KARPAS-45NUfMRZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7ETWM2OD1|N{[uNVYhdk1?MXLTRW5ITVJ?
SK-N-ASNYf5N4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTN6Nz64N{BvVQ>?MkP3V2FPT0WU
CTB-1MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnLTWM2OD12MEWuNFIhdk1?NWewNFcyW0GQR1XS
NKM-1MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTRzMT64PUBvVQ>?MVTTRW5ITVJ?
HTC-C3NFLXfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrVXmoxUUN3ME20N|IvQTVibl2=NVLNZm5jW0GQR1XS
BE-13MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTR2ND6yO{BvVQ>?NH7mWVRUSU6JRWK=
KOSC-2M1fVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;welhKSzVyPUS2Ok46KG6PNV[4UY1CW0GQR1XS
NB14MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPQSY9KSzVyPUS4N{42QCCwTR?=M1mybnNCVkeHUh?=
CAL-27M4HHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF60WXRKSzVyPUS5OE42QSCwTR?=MYPTRW5ITVJ?
H9M3yweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLmTWM2OD12OUWuOFMhdk1?M1SxPHNCVkeHUh?=
RS4-11MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTYTWM2OD13MESuO|Mhdk1?NE\YWm5USU6JRWK=
PA-1NVPtcZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7pXZZKSzVyPUWwPU45PiCwTR?=Ml;sV2FPT0WU
MV-4-11NHfVT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnFTWM2OD13MUOuPFUhdk1?NF7ycXFUSU6JRWK=
OS-RC-2NIrEbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1z3TWlEPTB;NUKxMlYzKG6PM4PBRnNCVkeHUh?=
RPMI-8226NGG5RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG0TWM2OD13Mk[uPFYhdk1?NXjQZ|lEW0GQR1XS
HGC-27M1fRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjHWlhKSzVyPUW2OE46QSCwTR?=NVi0PJpyW0GQR1XS
CHP-212NFHyNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HE[WlEPTB;NUmzMlU6KG6PNIrNeFZUSU6JRWK=
NB10Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\1U|VKSzVyPUW5PU4yQCCwTR?=M2flU3NCVkeHUh?=
HHNV;JTpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXi0VXJEUUN3ME21PVkvPDNibl2=MVzTRW5ITVJ?
EW-16NV36fHozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELnW4xKSzVyPU[wN{42OiCwTR?=NWPxdpdPW0GQR1XS
ES8NGPUbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTZyNT6yNUBvVQ>?NVnDPWNIW0GQR1XS
HAL-01MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\4TWM2OD14MEWuOlchdk1?NUXnU|NpW0GQR1XS
A204M1zMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETqeG1KSzVyPU[zN{46OSCwTR?=NXfkT3pZW0GQR1XS
MHH-PREB-1NF7EXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2eyV2lEPTB;NkO2Mlk6KG6PNGLXWIpUSU6JRWK=
EM-2NGnERXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTZ3MD62OEBvVQ>?M2G3UHNCVkeHUh?=
BV-173MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfMN2JYUUN3ME22OVIvPDhibl2=NWDOXG95W0GQR1XS
ONS-76M3XzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mof1TWM2OD14N{euPFIhdk1?MmLVV2FPT0WU
KM-H2M{PYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LnOGlEPTB;Nkm1MlU1KG6PNVzXS4R4W0GQR1XS
D-263MGMkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjlVJFKSzVyPUexO{4yOiCwTR?=M3jZfnNCVkeHUh?=
ES3MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[5TWM2OD15MkiuPVMhdk1?MWDTRW5ITVJ?
VA-ES-BJMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvxfVd2UUN3ME23N|IvOjdibl2=NYe3cldCW0GQR1XS
NBsusSRMoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnWfJBKSzVyPUe0Nk46QSCwTR?=NITrOHRUSU6JRWK=
NCI-H520NH\ldFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTHTWM2OD15NE[uOVIhdk1?NVy2Z4hOW0GQR1XS
ES5NYXTV5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PzcWlEPTB;N{WyMlghdk1?NWfxUWk1W0GQR1XS
T-24NXjIRVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjS[mxKSzVyPUe3PE44OSCwTR?=MWLTRW5ITVJ?
SW962NYrlNXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRThyOD62N{BvVQ>?NVrPVWZGW0GQR1XS
EW-3NH7zXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRThyOD63OkBvVQ>?MW\TRW5ITVJ?
RXF393M{Dp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXxRo5KSzVyPUixNk44QSCwTR?=NYHoUW5NW0GQR1XS
U251MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRThzMz64PEBvVQ>?NXHmT2dZW0GQR1XS
CAMA-1Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTEfJpkUUN3ME24N|MvQTRibl2=NEfhTJpUSU6JRWK=
JVM-3MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3CS5VKSzVyPUi1NU44QCCwTR?=MnTMV2FPT0WU
COLO-800M4LzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvxTWM2OD16OUeuO|ghdk1?MXrTRW5ITVJ?
OVCAR-5MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfwb2pKSzVyPUmwNE4yKG6PMlfMV2FPT0WU
LB1047-RCCMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\lOWlEPTB;OUK3MlU3KG6PNXSzZmVVW0GQR1XS
SW954MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TaOmlEPTB;OUK5MlQyKG6PMkOxV2FPT0WU
J-RT3-T3-5MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjYTWM2OD17M{[uNFYhdk1?M3rwcnNCVkeHUh?=
MewoMnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlH0TWM2OD17M{[uOkBvVQ>?MUDTRW5ITVJ?
NCI-H1770Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDQTWM2OD17NECuOVUhdk1?MoPQV2FPT0WU
HO-1-N-1M1qxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonjTWM2OD17NkKuPFEhdk1?NFy3Z5dUSU6JRWK=
HSC-3Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO5SppkUUN3ME25OlYvPDhibl2=Mo\0V2FPT0WU
TYK-nuMoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTl7OD6yOUBvVQ>?MYHTRW5ITVJ?
KYSE-150M37OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTFwMECwO|Yh|ryPMV;TRW5ITVJ?
SN12CNUHnVZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33VWWlEPTB;MT6wNFg4PSEQvF2=Mm[zV2FPT0WU
MOLT-13MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwMEG0NlEh|ryPM{\YTXNCVkeHUh?=
TE-11MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLjSFJkUUN3ME2xMlA1QDF{IN88US=>MYjTRW5ITVJ?
DBMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFwMEeyO|Mh|ryPMU\TRW5ITVJ?
CAL-39MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HyNmlEPTB;MT6wO|UzOiEQvF2=MkHxV2FPT0WU
A3-KAWNX:2XoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LVXGlEPTB;MT6wPFQxQCEQvF2=NELOUZBUSU6JRWK=
CHP-134MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTFwMUG4NFch|ryPM4ntb3NCVkeHUh?=
TGWNUT3W5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTFwMUKzPVUh|ryPMUXTRW5ITVJ?
QIMR-WILMkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwMUOxN|Qh|ryPMVXTRW5ITVJ?
NCI-SNU-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nBV2lEPTB;MT6xOlM2PCEQvF2=M1SzOnNCVkeHUh?=
CGTH-W-1M1PPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTFwMUexPFYh|ryPMl75V2FPT0WU
MHH-ES-1M{TKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXPenBKSzVyPUGuNVc6QDZizszNNFG2ZndUSU6JRWK=
LB2241-RCCNHnGS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzzXHpPUUN3ME2xMlE5PjJizszNM3HVe3NCVkeHUh?=
ML-2NYXDUnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHzV29KSzVyPUGuNlA4OzRizszNMoDtV2FPT0WU
COR-L23NHTGcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTFwMkK5N|Mh|ryPM3zRPXNCVkeHUh?=
BFTC-905NH\SN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFwMkSyOlch|ryPMl;lV2FPT0WU
Hs-578-TM{i1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTFwMkW4NVch|ryPM2Tl[XNCVkeHUh?=
KG-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHGTWM2OD1zLkK2Olg3KM7:TR?=MlPmV2FPT0WU
HELNYnYSYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnP[GU1UUN3ME2xMlI6OzN6IN88US=>MnXLV2FPT0WU
A549NYPReVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHftdYlKSzVyPUGuNlk{QTlizszNNU\acXVGW0GQR1XS
COLO-741MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjXTWM2OD1zLkOyNFg6KM7:TR?=M4PTOnNCVkeHUh?=
PC-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnDWYFKSzVyPUGuN|UzOjFizszNNFHKOYpUSU6JRWK=
HOSNX;OVJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[x[GlEPTB;MT6zOVI6PiEQvF2=MlzXV2FPT0WU
HT-1080MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTFTWR6UUN3ME2xMlM4PTF7IN88US=>NYTPbXVGW0GQR1XS
TE-8NXfme5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWwe4FKSzVyPUGuOFE4PzRizszNNY\DSGdVW0GQR1XS
BHYMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\4[oRKSzVyPUGuOFY6OjNizszNNHTJSYNUSU6JRWK=
BB65-RCCMoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHXdFRKSzVyPUGuOVA2OjhizszNNG\zU3VUSU6JRWK=
HNMlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nSXWlEPTB;MT61OFA4OSEQvF2=NYD1VXBlW0GQR1XS
NCI-H441NIXNbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4L2SWlEPTB;MT61OFkxPyEQvF2=NEXsUJVUSU6JRWK=
RPMI-8866NWqxVWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlS5TWM2OD1zLkW4OVA4KM7:TR?=M3nZUHNCVkeHUh?=
CAL-62M1TWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTMXFlKSzVyPUGuOlA5PjJizszNM{e0[HNCVkeHUh?=
MG-63M2XydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTFwNkG4NVMh|ryPMmjhV2FPT0WU
SK-LU-1M{Hlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zuXWlEPTB;MT62NlE2OiEQvF2=MmLtV2FPT0WU
BCPAPM1zq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXZV4Q6UUN3ME2xMlY3PDV5IN88US=>MYjTRW5ITVJ?
22RV1MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWf4cpNOUUN3ME2xMlY4QDR|IN88US=>NUfSWnp1W0GQR1XS
T47DNXr3UpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwNkiwOlEh|ryPMmDmV2FPT0WU
MSTO-211HMmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFGyS|ZKSzVyPUGuOlk3ODNizszNNVrOW5RtW0GQR1XS
DELNUnmU3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwN{CyO|Mh|ryPMl7hV2FPT0WU
H4NWPNd4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrPbXJKSzVyPUGuO|MzOTJizszNNXK1VHVSW0GQR1XS
CAL-51MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTFbnFPUUN3ME2xMlc1QDV3IN88US=>MXTTRW5ITVJ?
ABC-1NFO1NmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfhcWZKSzVyPUGuO|g2QDJizszNM1\ONHNCVkeHUh?=
MZ2-MELMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Due2lEPTB;MT63PVU1OiEQvF2=MWPTRW5ITVJ?
YKG-1M1LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHOSodzUUN3ME2xMlgyODZzIN88US=>NVPMNlJmW0GQR1XS
KM12NWGwOZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK1cJlKSzVyPUGuPFE3ODJizszNM4mwbnNCVkeHUh?=
L-363NGjjdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\TTWM2OD1zLki3OFEzKM7:TR?=NXziRm5mW0GQR1XS
KU812NIC4PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;qTWM2OD1zLki5NlgzKM7:TR?=NXTuRmdoW0GQR1XS
LOXIMVINIq0VW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLBSG9bUUN3ME2xMlkyOjJ6IN88US=>M{T3N3NCVkeHUh?=
G-401MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFwOUK0Nlgh|ryPNFT0UoVUSU6JRWK=
SW780NV\TSGozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTDUFJuUUN3ME2xMlk3OjR4IN88US=>MmTJV2FPT0WU
SW872NWXZOZFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlX6TWM2OD1zLkm4N|Mh|ryPNVrOZWFEW0GQR1XS
NB7NV63cndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvNTWM2OD1zLkm5N|I{KM7:TR?=NFvMWJJUSU6JRWK=
T98GM{\nN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mof3TWM2OD1{LkCwOlY3KM7:TR?=NV7LVYJ2W0GQR1XS
SW1710NHvjNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJwME[5OFUh|ryPMYnTRW5ITVJ?
NCI-H1573NXfLOWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmGxTWM2OD1{LkC3Nlk5KM7:TR?=NVPzV2JVW0GQR1XS
KE-37NVfBc4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJwMEi5OVEh|ryPNXrESo5sW0GQR1XS
786-0M17ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwMUW0N|kh|ryPMXXTRW5ITVJ?
SASMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWG4PG9uUUN3ME2yMlIxOzd2IN88US=>NEPNS5lUSU6JRWK=
CAL-54NX[wXW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2f1SmlEPTB;Mj6yNFQyOyEQvF2=M1nycnNCVkeHUh?=
SF268MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTJwMkOxNlIh|ryPNUPrcnJzW0GQR1XS
SW620NUXvN442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJwMk[xOlkh|ryPNUfyTY5qW0GQR1XS
MN-60NEnYVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJwM{GwOkDPxE1?M{nFTHNCVkeHUh?=
EFO-27NXuxcIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\TTWM2OD1{LkOyNFU5KM7:TR?=NEXEPZVUSU6JRWK=
NCI-H747NICxRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTJwM{KxPVkh|ryPM4Lob3NCVkeHUh?=
HCC2218MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PaWWlEPTB;Mj6zOVM4PCEQvF2=MorHV2FPT0WU
MIA-PaCa-2NUHJSm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TKU2lEPTB;Mj6zOlQ{PyEQvF2=M3TTSXNCVkeHUh?=
SJSA-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3H6XmlEPTB;Mj6zO|c6PiEQvF2=NF[3Rm1USU6JRWK=
RKOM4Lqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTJwM{i0PVYh|ryPNGW5PIlUSU6JRWK=
NB6MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUm3cJk{UUN3ME2yMlQxOzd2IN88US=>NH;rNoVUSU6JRWK=
ES4MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTJwNEW0NlIh|ryPNETzVHJUSU6JRWK=
EGI-1NXexW2Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPJTWM2OD1{LkS2PFg{KM7:TR?=NVTQUoxKW0GQR1XS
CTV-1MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfm[4dKSzVyPUKuOVI4PzNizszNNHPyTlBUSU6JRWK=
NCI-H1355M136Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:xcWlKSzVyPUKuOVU6PTFizszNNYjmRZRHW0GQR1XS
GT3TKBMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJwNUmxPVkh|ryPNHfsSWdUSU6JRWK=
SK-HEP-1NGjxWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHCV4FEUUN3ME2yMlU6OjZ4IN88US=>MnzMV2FPT0WU
GAMGMkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTJwNUmzPVQh|ryPNHPGcm9USU6JRWK=
SK-MES-1NYG3[WlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJwNkG4NFMh|ryPMlX5V2FPT0WU
RO82-W-1NV;CSnRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkK1TWM2OD1{Lk[yNFU4KM7:TR?=M2O3OHNCVkeHUh?=
ECC10M{fhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDkTWM2OD1{LkewNlA3KM7:TR?=Mn\CV2FPT0WU
MCF7MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfMTWM2OD1{LkexOFY1KM7:TR?=MYrTRW5ITVJ?
D-283MEDMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTGdmxKSzVyPUKuO|I1OyEQvF2=M4SxenNCVkeHUh?=
RPMI-7951M4DOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJwN{W2PVQh|ryPMUHTRW5ITVJ?
Ramos-2G6-4C10M2jjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\ER5hKSzVyPUKuO|cxQTlizszNMWDTRW5ITVJ?
KGNNGLzXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\YWmdKSzVyPUKuPFE5QDRizszNM1zBZXNCVkeHUh?=
NUGC-3MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnmzTWM2OD1{LkiyOVA2KM7:TR?=M{DYZ3NCVkeHUh?=
NCI-H292NXrZdGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3KTWM2OD1{Lki1NFU{KM7:TR?=NGXKdHFUSU6JRWK=
BeckerMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PEU2lEPTB;Mj65OVg{OiEQvF2=Mn\jV2FPT0WU
NCI-H1299NHXiN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTNwMEWyOlMh|ryPMmnmV2FPT0WU
ETK-1NH:2elNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLtTWM2OD1|LkC1OFMh|ryPNIOzWJhUSU6JRWK=
TK10NVXG[ItOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHWS5BKSzVyPUOuNlAyPjVizszNMki0V2FPT0WU
VMRC-RCZNX3SeHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIizXmtKSzVyPUOuN|Y1QDhizszNM2f1XXNCVkeHUh?=
YH-13MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWX6Z5VIUUN3ME2zMlQ1ODd7IN88US=>MV\TRW5ITVJ?
DU-145M1jvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTNwNE[yOlkh|ryPNYiy[2c1W0GQR1XS
SW1088NYHoZpVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlf0TWM2OD1|LkS3OFch|ryPNH7W[2JUSU6JRWK=
HOP-92MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXBU|RLUUN3ME2zMlUxOzR{IN88US=>MU\TRW5ITVJ?
KP-N-YSNEnFeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLETWM2OD1|Lk[yNVM6KM7:TR?=M{H6WnNCVkeHUh?=
NCI-H460M4OzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HLV2lEPTB;Mz62Olc{KM7:TR?=MW\TRW5ITVJ?
U-2-OSMkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXW[HZjUUN3ME2zMlczPTN3IN88US=>NFzKellUSU6JRWK=
A101DNH3ESG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUS0SnFEUUN3ME2zMlc3QTN4IN88US=>M4nkTXNCVkeHUh?=
MDA-MB-231NFHkTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\RfppPUUN3ME2zMlgyQTVzIN88US=>NYLKfmU3W0GQR1XS
IST-MES1MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkmxTWM2OD1|LkizNkDPxE1?NWfPXHlEW0GQR1XS
COR-L105MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTRwMEG4JO69VQ>?NYHhV|BMW0GQR1XS
NCI-H1437NUHOUXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7HTWM2OD12LkCyN|AzKM7:TR?=NIGxdHVUSU6JRWK=
CAL-85-1NGj6UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmKzTWM2OD12LkCyOFYyKM7:TR?=NGrFU4ZUSU6JRWK=
MZ1-PCNEHGUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnETWM2OD12LkG4OVU3KM7:TR?=NEXzZpZUSU6JRWK=
VM-CUB-1Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\Ec|FKSzVyPUSuN|EzQDRizszNMWTTRW5ITVJ?
CHL-1NUjG[lVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPwSnZ7UUN3ME20MlMzOTZ7IN88US=>Mn;pV2FPT0WU
MDA-MB-361NWS2XXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nJVGlEPTB;ND6zN|E2OyEQvF2=NWDyWo1zW0GQR1XS
NCI-H661NE\UZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDITWM2OD12LkWwNFkzKM7:TR?=NVjuZlRjW0GQR1XS
EW-11M4XjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTRwNUKyN|Eh|ryPMYPTRW5ITVJ?
BENM3nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;aWoFKSzVyPUSuOVI5OTVizszNNHG1PYRUSU6JRWK=
BFTC-909NIDzO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLyWJVKSzVyPUSuOVYzPzVizszNM3rsRXNCVkeHUh?=
NCI-H2087M{OxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4W5bmlEPTB;ND61PFE3PCEQvF2=M3rEcXNCVkeHUh?=
RVH-421MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTRwNk[2PUDPxE1?NFOwOJdUSU6JRWK=
P30-OHKNHrURmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HXUWlEPTB;ND62PFAxQCEQvF2=M{Pnc3NCVkeHUh?=
NCI-H28M1TUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYmxdGtOUUN3ME20MlgyPjZzIN88US=>MlrJV2FPT0WU
ES6M2SxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoS2TWM2OD12LkizNFE3KM7:TR?=NHL6RXpUSU6JRWK=
769-PNIP3eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\s[mlEPTB;ND64OVkzPiEQvF2=MmDMV2FPT0WU
OE33MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXDXotrUUN3ME20Mlg5OTZzIN88US=>NYXoVIJvW0GQR1XS
SW982NITR[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULNOWp7UUN3ME20Mlk2ODZzIN88US=>M1[5dXNCVkeHUh?=
A388NFKxRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLlUVRkUUN3ME21MlAzQTh|IN88US=>NVLEXmR1W0GQR1XS
TI-73MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPDW4FZUUN3ME21MlA3OTl2IN88US=>MVHTRW5ITVJ?
HCT-116M4P0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7xTWM2OD13LkC5PFg6KM7:TR?=M3LpZXNCVkeHUh?=
HuP-T3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWC3VHBMUUN3ME21MlE5PzB7IN88US=>NH\LZ2dUSU6JRWK=
G-402NV;zXFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\3d2lEPTB;NT6xPVQyPiEQvF2=MojpV2FPT0WU
NCI-H1792M3Themdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPMcYxKSzVyPUWuNlQ3OjJizszNMV3TRW5ITVJ?
NCI-H209NHT3S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDXTWM2OD13LkK1PVQzKM7:TR?=NEDEOG1USU6JRWK=
NCI-H1650MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfQN4lwUUN3ME21MlMxPjN2IN88US=>NYC0XpViW0GQR1XS
LCLC-97TM1M1nTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmeyTWM2OD13LkOxPFA5KM7:TR?=MYHTRW5ITVJ?
S-117MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;6SFZKSzVyPUWuN|Y6PzZizszNMmWxV2FPT0WU
GI-ME-NM{TDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17MemlEPTB;NT6zPVY5OSEQvF2=MXPTRW5ITVJ?
NCI-H2122MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoG2TWM2OD13LkS5N|k4KM7:TR?=NVjpeZByW0GQR1XS
NCI-H1793MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlS1TWM2OD13Lk[3OVk{KM7:TR?=NF3ifJhUSU6JRWK=
C2BBe1M33yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLQTWM2OD13LkewNFg5KM7:TR?=NIK1VHRUSU6JRWK=
TE-12NEPJR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zLUmlEPTB;NT64NFU2PiEQvF2=NID3fYFUSU6JRWK=
LCLC-103HMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDFNZUzUUN3ME21MlkyPyEQvF2=MlvIV2FPT0WU
A673M{PuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnNN3pTUUN3ME21MlkyQTN{IN88US=>MVHTRW5ITVJ?
BB30-HNCNXuxO28zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknQTWM2OD13Lkm4N|Yh|ryPMoriV2FPT0WU
SF295MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfTOGtKSzVyPU[uNFA1OjJizszNNV7ke3ZzW0GQR1XS
KU-19-19NVi3XZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTZwMEG3N|Eh|ryPMX7TRW5ITVJ?
CFPAC-1NFTPWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIqxU2RKSzVyPU[uNFQ1PDNizszNNV7TXphqW0GQR1XS
LoVoM13iSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLOTWM2OD14LkC1NFY{KM7:TR?=MYTTRW5ITVJ?
8505CMl;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjjd45KSzVyPU[uNFc2PzNizszNMWHTRW5ITVJ?
GMS-10M1m0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\2e3F3UUN3ME22MlE2ODB{IN88US=>NXvG[4x2W0GQR1XS
Ca9-22MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\uc|JKSzVyPU[uNVY4OSEQvF2=MYHTRW5ITVJ?
DOKNYXabWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTZwMkKwO|Ih|ryPMXLTRW5ITVJ?
FADUM4H6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVq5bHpxUUN3ME22MlI3ODN7IN88US=>M37qNnNCVkeHUh?=
BxPC-3MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXDT4ZKSzVyPU[uNlc{OiEQvF2=MlLVV2FPT0WU
CAL-33MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfzNXZKSzVyPU[uNlkzODFizszNNYLINoVFW0GQR1XS
SHP-77M3LrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTZwM{G1NVIh|ryPM4XNeHNCVkeHUh?=
LXF-289MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLEfndkUUN3ME22MlM{PDV3IN88US=>MX;TRW5ITVJ?
GB-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LaT2lEPTB;Nj6zPFIh|ryPNUHhbZBjW0GQR1XS
KS-1MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEG4OZRKSzVyPU[uN|g1PDdizszNMVrTRW5ITVJ?
D-502MGM2rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTZwNEKzO|Yh|ryPM{e0enNCVkeHUh?=
LAN-6NWC3S2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n2UWlEPTB;Nj61NVAzOyEQvF2=M3LPdHNCVkeHUh?=
H-EMC-SSNVzIS5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2m1bmlEPTB;Nj61OlE1PyEQvF2=MYPTRW5ITVJ?
LC-2-adMmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTZwNkCwO|Yh|ryPMlHPV2FPT0WU
NCI-H1693MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjZTWM2OD14Lk[yNlE2KM7:TR?=MVzTRW5ITVJ?
SK-N-FINXLKZnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzKTWM2OD14Lke1NFQ1KM7:TR?=MYDTRW5ITVJ?
D-423MGNX\1XJBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\m[lRCUUN3ME22Mlc3OTF5IN88US=>NFjJeZJUSU6JRWK=
KNS-42NIHHdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHnTWM2OD14Lke4NVk4KM7:TR?=MVfTRW5ITVJ?
GCTNVvBN|NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTZwOUO4JO69VQ>?M3LqNnNCVkeHUh?=
DSH1MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33pZWlEPTB;Nz6wOlM{KM7:TR?=M{P1bHNCVkeHUh?=
D-247MGMnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nVWmlEPTB;Nz6wO|g5OSEQvF2=NUDHNWdMW0GQR1XS
NCI-SNU-5MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHrcFlYUUN3ME23MlE5OzdzIN88US=>NHf3V5pUSU6JRWK=
TE-6NEfGV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37IWGlEPTB;Nz6yNFYxOSEQvF2=NXzZcpR5W0GQR1XS
NOMO-1NYeyUohFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTdwMkKxNlch|ryPMnfLV2FPT0WU
NB17MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3aTWM2OD15LkOwN|A6KM7:TR?=NW\Ld452W0GQR1XS
EW-22NHnDNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TYVGlEPTB;Nz6zOFM1QCEQvF2=MXPTRW5ITVJ?
EW-13MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTdwM{WxOlIh|ryPM3;vVXNCVkeHUh?=
DOHH-2MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHftNoFKSzVyPUeuOFQxOiEQvF2=M1rXXXNCVkeHUh?=
TGBC1TKBNGLl[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\4TWM2OD15LkS5PFk6KM7:TR?=M2LIeXNCVkeHUh?=
GR-STM4rJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGj0ZWhKSzVyPUeuOVI2QTRizszNNGPCZ2lUSU6JRWK=
KYSE-520NUO4PGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPne5UxUUN3ME23MlU2PTF3IN88US=>NIrLTHZUSU6JRWK=
CAPAN-1MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLoW5FKSzVyPUeuOVk2OSEQvF2=M3HBd3NCVkeHUh?=
HCE-4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\Te|B3UUN3ME23MlYzOjd7IN88US=>M1zZNHNCVkeHUh?=
MLMANUPvUHpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHmNWJ1UUN3ME23MlYzQTV5IN88US=>M1vaXHNCVkeHUh?=
HT-144M{fZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TqUmlEPTB;Nz62OVM3QCEQvF2=MnXnV2FPT0WU
KYSE-180NIHob25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGftXppKSzVyPUeuO|EyPjlizszNMnPWV2FPT0WU
TE-5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTdwOUW5O|Eh|ryPNHrGeIxUSU6JRWK=
IGROV-1NIHjOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rqbmlEPTB;Nz65PFU2OSEQvF2=M3\PfXNCVkeHUh?=
NCI-H1581M3jMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M331eGlEPTB;OD6wNVIh|ryPMoXwV2FPT0WU
SW1990NGPYZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRThwMES2OVkh|ryPMkHXV2FPT0WU
EFM-19MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvWboFKSzVyPUiuNFg2PDVizszNMV;TRW5ITVJ?
OGR-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRThwNEOwNlMh|ryPMn7KV2FPT0WU
U-118-MGNGPiNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fyTGlEPTB;OD60N|Q3OyEQvF2=MmXkV2FPT0WU
SK-OV-3NEXzXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXY[I5KSzVyPUiuOFY4PjVizszNNEfKbYVUSU6JRWK=
KNS-62M2XEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPMbXdKSzVyPUiuOVE4PjFizszNNGDQPWVUSU6JRWK=
GOTOMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHIb3ZIUUN3ME24MlU4PjN3IN88US=>MX7TRW5ITVJ?
8305CMlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRThwN{C0PFQh|ryPM16zdXNCVkeHUh?=
RPMI-2650M2L4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmH1TWM2OD16LkexPVU2KM7:TR?=NGewOmhUSU6JRWK=
NEC8M1Pi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPiU4VHUUN3ME24Mlc1OzB5IN88US=>MnrmV2FPT0WU
KYSE-450NHLFS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHP2OGNKSzVyPUiuPFY2PDhizszNM3;aOnNCVkeHUh?=
RMG-IMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX[4eFdFUUN3ME25MlE1ODV6IN88US=>NWrSTopiW0GQR1XS
CAKI-1NFrOWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXT6T45vUUN3ME25MlMyQTd7IN88US=>NXfSTpc3W0GQR1XS
KYSE-510NX;RVFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkm5TWM2OD17LkO1O|c5KM7:TR?=NHSxcnpUSU6JRWK=
A4-FukNYjvUmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFW5N2JKSzVyPUmuN|Y4ODFizszNM1[2dHNCVkeHUh?=
AN3-CAMkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTlwNEW0OFQh|ryPMoL6V2FPT0WU
SK-N-DZMn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPlV5BKSzVyPUmuO|I5PDlizszNMXrTRW5ITVJ?
HSC-2M{HE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTlwN{[2Nlkh|ryPM4D0bXNCVkeHUh?=
EW-1MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELObGVKSzVyPUmuO|k{PjlizszNNWOyXXZQW0GQR1XS
D-566MGNIfLNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTlwOEO2OlQh|ryPMVTTRW5ITVJ?
COLO-792NFvMTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWO0eFRjUUN3ME25Mlk5PzR4IN88US=>MUnTRW5ITVJ?
TE-10M1XPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LSeWlEPTB;MUCuNFM6PiEQvF2=M3y3OHNCVkeHUh?=
NCI-H650M{fNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjzUXdqUUN3ME2xNE41Ojh4IN88US=>MVPTRW5ITVJ?
U-266NWToblVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPqVFZMUUN3ME2xNE41PTVizszNMXrTRW5ITVJ?
Detroit562NXzGdGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETlWWdKSzVyPUGxMlA2OTVizszNM1nqd3NCVkeHUh?=
NH-12MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XWZ2lEPTB;MUGuNVQ1PiEQvF2=NUnlPVh2W0GQR1XS
CO-314MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDEfGxKSzVyPUGxMlI5PDJizszNMYnTRW5ITVJ?
IST-MEL1M1S2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPoTWM2OD1zMT61N|I{KM7:TR?=NGjGZnFUSU6JRWK=
KNS-81-FDMkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PPNGlEPTB;MUGuOVUzPyEQvF2=M1qyOHNCVkeHUh?=
SW1463MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\BRWlEPTB;MUGuOVk5QSEQvF2=NFXSWZpUSU6JRWK=
NCI-H23NHrzZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTFzLk[1OVIh|ryPNY\MdWptW0GQR1XS
SK-MEL-2NGLrdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTFzLkexPVch|ryPNXHRRpdLW0GQR1XS
NB13NF3RWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTF{LkG0PVUh|ryPNYrweGx3W0GQR1XS
DaoyMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF{LkK4OVYh|ryPM3Xye3NCVkeHUh?=
NCI-H1623NX21TWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjJdmtDUUN3ME2xNk4{QDBzIN88US=>MlnZV2FPT0WU
NMC-G1NFT5WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlv3TWM2OD1zMj63NVch|ryPMkDmV2FPT0WU
DK-MGMmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXUTW5KSzVyPUGyMlk1QDJizszNMkflV2FPT0WU
TCCSUPMlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF|LkGyPFQh|ryPMnS5V2FPT0WU
SCC-15NUPJPYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVH5OYRoUUN3ME2xN{4zPjVzIN88US=>NWPaZYJ6W0GQR1XS
NOS-1MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLYcZMyUUN3ME2xN{4zQDl|IN88US=>MknNV2FPT0WU
RH-1M1PWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDhcpJSUUN3ME2xN{4{ODN5IN88US=>MnnMV2FPT0WU
SK-MEL-3Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXJbJVKSzVyPUGzMlM4OjhizszNM2jrNXNCVkeHUh?=
NB5MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfSO5NjUUN3ME2xN{41ODZ5IN88US=>NYTFVIdlW0GQR1XS
SNU-387NXywNpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF73O4ZKSzVyPUGzMlUxPzJizszNMlP3V2FPT0WU
CAL-120MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXobZJKSzVyPUGzMlY4OThizszNM4X5RnNCVkeHUh?=
Mo-TNIrqSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoD2TWM2OD1zMz63NFch|ryPMUfTRW5ITVJ?
LNCaP-Clone-FGCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkKwTWM2OD1zMz63PVkzKM7:TR?=MYTTRW5ITVJ?
CANMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLVNFRKSzVyPUG0MlAzQDhizszNMn:3V2FPT0WU
SK-MEL-30NH\jdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HZR2lEPTB;MUSuNFY{KM7:TR?=NXHMU4lXW0GQR1XS
COLO-678NHXHUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTF2LkC4NlIh|ryPNEn6SZRUSU6JRWK=
SCC-9NFSyc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TETmlEPTB;MUSuNVAzOSEQvF2=NX:z[5BSW0GQR1XS
KINGS-1NWfjfYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrqTWM2OD1zND6xOFAzKM7:TR?=NV76PHQ5W0GQR1XS
SL-513MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF2LkG4O{DPxE1?MUHTRW5ITVJ?
HLEM2[yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\vOJlKSzVyPUG0MlM5PTJizszNM2XCXnNCVkeHUh?=
SW1573M1\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF2LkS0N|Uh|ryPMV7TRW5ITVJ?
KYSE-140NXLKWmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPjTWM2OD1zND62N|I4KM7:TR?=NGX5VHhUSU6JRWK=
SK-PN-DWNHj4XnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfRTWM2OD1zND64NFAyKM7:TR?=MYfTRW5ITVJ?
A253NYPmbVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zHS2lEPTB;MUWuNFYzPSEQvF2=NYi4RWF{W0GQR1XS
CAL-12TMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGOybGdKSzVyPUG1MlQ3PjJizszNNXvtXlJ1W0GQR1XS
COLO-679NEmzdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTF3Lke2PFMh|ryPNETueItUSU6JRWK=
UACC-257NVqzbIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTF4LkGyNFEh|ryPNFPPTnZUSU6JRWK=
U-87-MGNYPjVIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGe0[JdKSzVyPUG2MlM2OjNizszNNGfLRW5USU6JRWK=
HCC1806NFfLb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlv4TWM2OD1zNj63NFcyKM7:TR?=NYLsXpJCW0GQR1XS
NCI-H2170M4nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrWVWlKSzVyPUG3MlI1PDhizszNNUX0PJV{W0GQR1XS
AGSMkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfCTWM2OD1zNz6zPFA5KM7:TR?=M1rteHNCVkeHUh?=
MEL-HONFXM[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrMb2NrUUN3ME2xO{44PTB|IN88US=>NVPlU4V4W0GQR1XS
SW48M{\Odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mki4TWM2OD1zNz63O|E3KM7:TR?=NX75RVlXW0GQR1XS
HuP-T4M{fj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf4boh4UUN3ME2xPE4xOjB4IN88US=>MVXTRW5ITVJ?
NCI-H720MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF6LkG0NFIh|ryPMWnTRW5ITVJ?
RCC10RGBM37Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PwZmlEPTB;MUiuNVY6PyEQvF2=NETJbWFUSU6JRWK=
HD-MY-ZMmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF6LkKyOVQh|ryPNIn1fZFUSU6JRWK=
A427MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPpOWhKSzVyPUG4MlUxQTRizszNNV7jN2ZrW0GQR1XS
HCC2998MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkiyTWM2OD1zOD62NFUyKM7:TR?=MkjxV2FPT0WU
EPLC-272HNXL4UWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[2cWlEPTB;MUmuNFQ{PCEQvF2=NUC1TIpvW0GQR1XS
C32M37jVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUKyWmU3UUN3ME2xPU4xPDVizszNNXHpdpFmW0GQR1XS
UMC-11M{fZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF7LkKxNlMh|ryPNGrYWnBUSU6JRWK=
CaR-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrlTWM2OD1zOT62PFA1KM7:TR?=M4HtTHNCVkeHUh?=
KYSE-410MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfUTWM2OD1zOT65NVM6KM7:TR?=NHfrVXhUSU6JRWK=
HuCCT1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XIc2lEPTB;MkCuOlI6PCEQvF2=MXjTRW5ITVJ?
LB996-RCCMoj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zJS2lEPTB;MkCuO|E3QCEQvF2=NGX3dllUSU6JRWK=
KYSE-70NXTGVGNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TwR2lEPTB;MkCuPFA2QSEQvF2=MoLnV2FPT0WU
CAL-72MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrKWXpKSzVyPUKwMlkyPSEQvF2=NFjoNo1USU6JRWK=
Capan-2MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XifWlEPTB;MkGuNFQyOyEQvF2=MV\TRW5ITVJ?
PANC-08-13MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrjN5lzUUN3ME2yNU4zPTF3IN88US=>M2nFdHNCVkeHUh?=
SBC-1NFjNXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELGUYVKSzVyPUKxMlMxQDFizszNMYHTRW5ITVJ?
MFM-223NYjYPZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTiTWM2OD1{MT6zN|QzKM7:TR?=MoW1V2FPT0WU
BB49-HNCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfjTWM2OD1{MT61O|E3KM7:TR?=M{TGdHNCVkeHUh?=
SH-4NV;rbZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJzLk[2NVgh|ryPM1X6S3NCVkeHUh?=
HuO9NYfyfnVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTCbXc5UUN3ME2yNU46QDJ3IN88US=>MmrZV2FPT0WU
AM-38MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoD3TWM2OD1{Mj6wOFg2KM7:TR?=NWH4dVNvW0GQR1XS
A431NV;qVVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3yXWtzUUN3ME2yN{4zOTF7IN88US=>MknqV2FPT0WU
YAPCNWO0eY57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJ|LkK2OVEh|ryPNE\ONpZUSU6JRWK=
LU-139NXTKd|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHoWpNKSzVyPUKzMlQ5ODlizszNNYTjVIszW0GQR1XS
HEC-1MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\YTWM2OD1{Mz60PVM4KM7:TR?=NIPaSoxUSU6JRWK=
SCC-25MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXjfVNqUUN3ME2yOE4{ODB4IN88US=>NXO2fXZ[W0GQR1XS
HT-29NV\LNHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPXUlZNUUN3ME2yOE4{QDJ|IN88US=>NXnHb5VmW0GQR1XS
PC-14MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljhTWM2OD1{ND62OVcyKM7:TR?=MUPTRW5ITVJ?
Calu-6MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXKNYxKSzVyPUK1MlUxPzFizszNNXTQR4xJW0GQR1XS
SJRH30NEHKN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LHbGlEPTB;MkWuOlQ6PiEQvF2=NGHv[2RUSU6JRWK=
ChaGo-K-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjLWmQzUUN3ME2yOk4yPjJ7IN88US=>NXf5Z2RMW0GQR1XS
IA-LMMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPhUXp5UUN3ME2yOk4{PjR3IN88US=>NVrSWYVrW0GQR1XS
GP5dMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnJ[5lyUUN3ME2yOk41PDlzIN88US=>MV7TRW5ITVJ?
NCI-H2291NHznPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vOcGlEPTB;Mk[uOlU1OSEQvF2=MVLTRW5ITVJ?
BALL-1MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;r[3BwUUN3ME2yOk46Ozl5IN88US=>NVy0W21QW0GQR1XS
HCC1954NIrIS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jFUGlEPTB;Mk[uPVgxQCEQvF2=NYLGVmR3W0GQR1XS
NCI-H2452MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnftTWM2OD1{Nz60NVY{KM7:TR?=M{HPWXNCVkeHUh?=
LU-99AM1vPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJ5LkW1PFIh|ryPNUW5[YpJW0GQR1XS
NTERA-S-cl-D1NGP5Vo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3THS2lEPTB;MkeuO|I6QSEQvF2=M2iyRXNCVkeHUh?=
PANC-10-05MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfFTWM2OD1{Nz63O|c2KM7:TR?=MWrTRW5ITVJ?
NCI-H2405NXnzbZFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPHTWM2OD1{Nz65N|g4KM7:TR?=MmOwV2FPT0WU
MDA-MB-415M4T3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rJXWlEPTB;MkiuOFE{PyEQvF2=MmGzV2FPT0WU
NCI-H2342MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJ6LkWyPFEh|ryPMUnTRW5ITVJ?
TGBC24TKBNFr1XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K0O2lEPTB;MkiuO|EyPyEQvF2=MlHBV2FPT0WU
LU-134-ANVnTSGhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFyzcHdKSzVyPUK4MlkzPjFizszNMVfTRW5ITVJ?
SCC-4M{PhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3ZUG1ZUUN3ME2zNU4xPDl2IN88US=>MWHTRW5ITVJ?
Saos-2MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTNzLkmzNFYh|ryPNUTiXmNQW0GQR1XS
RERF-LC-MSM2TDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUOyd5NkUUN3ME2zNk45OjNzIN88US=>MnPSV2FPT0WU
M14NWTveWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXiblhLUUN3ME2zNk46PzZ2IN88US=>NVP0S4NmW0GQR1XS
HPAF-IIMljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPGV5FKSzVyPUOzMlUxOTFizszNMUPTRW5ITVJ?
NCI-H1755NWLWUld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrGTWM2OD1|ND6zN|A2KM7:TR?=M2Pkd3NCVkeHUh?=
D-392MGMnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{C5N2lEPTB;M{WuPFY4PCEQvF2=NVjxXmV5W0GQR1XS
A704NX3ZPGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nRfGlEPTB;M{[uNFQzPyEQvF2=NXruemRWW0GQR1XS
CP50-MEL-BM1vrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33TO2lEPTB;M{[uNVkyOSEQvF2=NVHtO|VIW0GQR1XS
EW-18M{PCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnu0TWM2OD1|Nj60OVIh|ryPNVP1dnlkW0GQR1XS
WM-115M{jTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjJcGhrUUN3ME2zOk45ODl7IN88US=>MU\TRW5ITVJ?
LU-65MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTN5LkG0NVch|ryPMoLQV2FPT0WU
NCI-H1563MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjrT21KSzVyPUO3MlI1QDRizszNM4TzTXNCVkeHUh?=
DBTRG-05MGMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{P5XWlEPTB;M{iuNFY6OSEQvF2=NV3nOWtoW0GQR1XS
NCI-H630NYjybHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN6LkS3NVQh|ryPNWP1PWRtW0GQR1XS
NCI-H1155MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHzd4FmUUN3ME2zPU4zPDJizszNMnrSV2FPT0WU
OVACR-3NV;lflgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoSxTWM2OD1|OT65NVk2KM7:TR?=M4\2cXNCVkeHUh?=
OAW-42MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfDUo5KSzVyPUSwMlQzPThizszNNWPKfHdmW0GQR1XS
JVM-2NIHqOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLpUoxWUUN3ME20NU4zPDF3IN88US=>MXHTRW5ITVJ?
C3ANEH5PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDxWJBZUUN3ME20NU4{PDR5IN88US=>MlnoV2FPT0WU
HT55MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTJW5FTUUN3ME20Nk4zQDRzIN88US=>MnvEV2FPT0WU
OVCAR-4MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHWXo9KSzVyPUSyMlI6PzRizszNMlPFV2FPT0WU
MEG-01MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTR{LkS2NVYh|ryPM1Ww[XNCVkeHUh?=
NCI-H82M1z0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTR|Lkm4PVIh|ryPM{X0d3NCVkeHUh?=
JEG-3M4rmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTR2Lkm0O{DPxE1?NYXvNlhPW0GQR1XS
BPH-1MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3iTWM2OD12Nj6zPVk5KM7:TR?=M1u5dHNCVkeHUh?=
MPP-89MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTR5LkK4PVgh|ryPNEHPOo5USU6JRWK=
ALL-POM4XDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnqWIxIUUN3ME20O{41OTh6IN88US=>MWTTRW5ITVJ?
HTMm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;1dGlEPTB;NEeuOFkzKM7:TR?=MkG1V2FPT0WU
NCI-H2347M1u2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTR6LkC3NVUh|ryPMXnTRW5ITVJ?
A2780MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\6PHpKSzVyPUS5MlQzOjhizszNNX\0OZVKW0GQR1XS
KARPAS-299M1Hv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi2c|lKSzVyPUS5MlUyOTlizszNNUHIUJJqW0GQR1XS
NCI-H1651NHnXTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLJTWM2OD12OT64PFIyKM7:TR?=MUPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02668666 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Brea  ...more Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Bi  ...more Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium June 2016 Phase 2
NCT02806050 Not yet recruiting Breast Cancer University Medical Center Groningen June 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warming (6.19 mM)
Ethanol <1 mg/mL
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Frequently Asked Questions

  • Question 1
    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

    Answer: This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib (LY2835219)

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us